young-professional-team-discussing-business-plan-i-2022-02-02-21-53-56-utc-scaled-e1657877

LeukoSight

business-people-shake-hands-in-the-office-e1655897424318.jpg

More About Us

We Like to Meet Entrepreneurs

While we invest at Series A (generally, when a company is over $2M in revenue), we like to meet founders before they’re raising their Series A – to build a relationship, learn more about the company, and allow them to get to know us. Please do reach out.

ABOUT US

New Markets Team

Mark Grovic

Co-Founder and General Partner

Follow Us On

Status

Realized

Location

Visit

Leukosight, Inc is a privately held biopharmaceutical company developing a novel line of anti-inflammatory therapeutics to address the medical needs of patients with acute or chronic autoimmune/inflammatory diseases. Focusing on small molecule therapeutics and delivery system for rheumatoid arthritis, Crohn’s and asthma.

In July of 2012, LeukoSight, Inc. received Phase I Small Business Technology Transfer funding from the NIH.